Search company, investor...

Seno Medical Instruments

senomedical.com

Founded Year

2005

Stage

Loan | Alive

Total Raised

$64.48M

Last Raised

$680K | 3 yrs ago

About Seno Medical Instruments

Seno Medical was formed to commercialize a new modality in cancer screening and diagnosis: laser opto-acoustic imaging. Unlike most screening techniques, which rely on anatomical imaging, Seno's goal is to bring functional imaging that can detect angiogenesis to the marketplace. Products for use with humans, focusing initially on breast cancer, are also in development for subsequent testing. Seno's patented technology integrates the use of lasers and acoustics to determine the presence of angiogenesis - the growth of blood vessels and higher blood volume that always surrounds a tumor. Per the company, unlike anatomical imaging techniques, such as mammography, laser opto-acoustic imaging can detect breast cancer, for example, at its earliest clinically stage (2 mm. versus 10 mm. with mammography) without patient discomfort or exposure to harmful x-ray.

Headquarters Location

5253 Prue Road Suite 315

San Antonio, Texas, 78240,

United States

210-615-6501

Missing: Seno Medical Instruments's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Seno Medical Instruments's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Seno Medical Instruments

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Seno Medical Instruments is included in 4 Expert Collections, including Women's Health & Wellness.

W

Women's Health & Wellness

1,484 items

Startups focused on providing products and services catering to women's health and wellbeing.

M

Medical Devices

11,988 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

H

Health IT

7,901 items

Seno Medical Instruments Patents

Seno Medical Instruments has filed 76 patents.

The 3 most popular patent topics include:

  • Medical imaging
  • Acoustics
  • Medical ultrasonography
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/22/2016

8/30/2022

Medical imaging, Medical ultrasonography, Image processing, Medical physics, Ultrasound

Grant

Application Date

3/22/2016

Grant Date

8/30/2022

Title

Related Topics

Medical imaging, Medical ultrasonography, Image processing, Medical physics, Ultrasound

Status

Grant

Latest Seno Medical Instruments News

Seno Medical's Market-Ready Imagio® OA/US Breast Imaging System Launches at RSNA 2022, Booth 6120

Nov 27, 2022

News provided by Share this article Share this article The category defining Imagio® Breast Imaging System helps physicians differentiate between benign and malignant breast lesions using a novel combination of ultrasound and opto-acoustic technology. SAN ANTONIO, Nov. 27, 2022 /PRNewswire/ -- Seno Medical, makers of the Imagio® Breast Imaging System - a revolutionary new modality in breast imaging - will officially launch the commercially available system at the annual RSNA Scientific Assembly and Annual Meeting starting November 27 through December 1 in Chicago (Booth 6120). Recently recognized with a Gold Edison award, a Gold Medical Design Excellence Award, and as a semifinalist in the Minnies 2022 competition for its medical innovation, Seno's groundbreaking diagnostic breast cancer imaging system helps physicians differentiate between benign and malignant breast lesions using non-invasive opto-acoustic/ultrasound (OA/US) technology to provide information about breast lesions in real time, helping providers to characterize masses that may — or may not — require more invasive diagnostic evaluation. In this virtual demo, you'll see Imagio® and SenoGram® in action with a clinical demonstration of Opto-Acoustic/Ultrasound (OA/US) technology. Learn how the system works with examples of images that can differentiate malignant and benign breast tissue on screen and in color, with the painless, real-time OA/US scan. In support of the launch at RSNA, Seno Medical will bring its category-defining Imagio® System to the doorsteps of clinicians and healthcare providers throughout the USA with its mobile education and demonstration tour, Imagio® OA/US Road Show - Scans Across America . The hands-on tour, which began this summer and is scheduling stops across the country throughout the coming year, enables on-site demonstrations of the Imagio® System. The market-ready Imagio® System received supplemental premarket approval (PMA) from the Center for Devices and Radiological Health (CDRH) of the US Food & Drug Administration (FDA) in June of this year; it incorporates the latest in ultrasound imaging technology required for premier breast imaging centers, as well as advanced ultrasound technology integrated into the opto-acoustic probe, a new ultrasound probe, and elimination of redundant electronics, making this version of Imagio® ergonomic and truly disruptive for the marketplace with its novel technological advances. Tom Umbel, President and CEO of Seno Medical, commented, "The time has come for the market to start adopting and using this groundbreaking new hybrid modality for breast imaging, and we are proud to be showcasing it at RSNA." Breast biopsy procedures, caused by false-positive diagnostic assessments, cost the US healthcare system more than $2 billion per year.i Seno's Imagio® technology could significantly reduce those costs with its non-invasive OA/US innovation. Seno's OA/US system combines laser optics and grayscale ultrasound to provide fused functional and anatomical breast imaging. The opto-acoustic images provide a unique blood map in and around breast masses, while the ultrasound provides a traditional anatomical image. Through the appearance or absence of two hallmark indicators of cancer — angiogenesis and hypoxia — Seno Medical has shown that the Imagio® OA/US Breast Imaging System will be a more effective tool to help radiologists confirm or rule out malignancy compared with traditional diagnostic imaging modalities. And it does this without exposing patients to potentially harmful ionizing radiation (x-rays) or contrast agents. In addition to the novel imaging provided by the Imagio® System, Seno includes an artificial intelligence (AI) decision-support tool (SenoGram®) to aid physicians in interpreting the new images. This AI tool, along with training and certification, helps radiologists transition from ultrasound alone to OA/US imaging. Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to developing and commercializing a new modality in cancer diagnosis: opto- acoustic imaging. Originally approved by the US FDA in January 2021, Seno Medical's Imagio® Breast Imaging System fuses opto-acoustic technology with ultrasound (OA/US) to generate real-time functional and anatomical images of the breast. To learn more about Seno Medical's OA/US imaging technology and applications, visit www.SenoMedical.com . Indication statement: The Imagio® system is indicated for use by trained and qualified healthcare providers to evaluate palpable and non-palpable breast abnormalities in adult patients who are referred for diagnostic imaging breast work-up following clinical presentation or other imaging examinations such as screening mammography. i Vlahiotis A, Griffin B, Stavros AT, Margolis J. Analysis of utilization patterns and associated costs of the breast imaging and diagnostic procedures after screening mammography. Clinicoeconomics Outcomes Res 2018;10:157-1 SOURCE Seno Medical

Seno Medical Instruments Frequently Asked Questions (FAQ)

  • When was Seno Medical Instruments founded?

    Seno Medical Instruments was founded in 2005.

  • Where is Seno Medical Instruments's headquarters?

    Seno Medical Instruments's headquarters is located at 5253 Prue Road, San Antonio.

  • What is Seno Medical Instruments's latest funding round?

    Seno Medical Instruments's latest funding round is Loan.

  • How much did Seno Medical Instruments raise?

    Seno Medical Instruments raised a total of $64.48M.

  • Who are the investors of Seno Medical Instruments?

    Investors of Seno Medical Instruments include Paycheck Protection Program, MedCare Investment Funds, SATAI Network, Houston Angel Network and Texas Emerging Technology Fund.

  • Who are Seno Medical Instruments's competitors?

    Competitors of Seno Medical Instruments include Luxonus, Zerigo Health, Gammex, BioMarker Strategies, Direct Conversion, Micrima, Gamma Medica, Applied Spectral Imaging, NanoMR, Real Imaging and 18 more.

Compare Seno Medical Instruments to Competitors

M
Microwave Imaging System Technologies (MIST)

Microwave Imaging Systems Technology was founded in 1995 by Dr. Keith Paulsen and Dr. Paul Meaney of the Thayer School of Engineering and has developed a microwave-based, breast imaging system which aims to provide high-contrast images for breast cancer diagnostics. Per the company, the NIH has invested more than $6 million to develop and demonstrate the MIST system for tumor imaging. The company reports that testing on more than 150 patients has shown excellent detection of breast tumors.

T
Tripath Imaging (fka Autocyte)

Tripath Imaging (fka Autocyte) offers cervical cancer screening systems

O
Orison

Orison Corporation was founded to design, manufacture and market a ultrasound technology platform for early breast cancer detection and diagnosis. Orison's technology aims to utilize Full Field Digital Ultrasound (FDDU) as an enabler that aims to allow the radiologist, for a time, to view breast tissue in a three dimensional environment. The outcome is earlier detection of breast cancer prior to metastasis, resulting in greater five-year survival rates and decreased treatment costs.

R
Real Imaging

Real Imaging is developing an imaging solution for breast cancer detection which is both accurate and patient-friendly. Real imaging's MIRA technology will increase correct detection rates and decrease the amount of false diagnoses for women of all ages around the globe.

Micrima Logo
Micrima

Micrima is a Bristol-based company developing a safe, low-cost system to improve the detection of breast cancer. The imaging system captures high-resolution, 3D images through the use of harmless radio waves. The safe, low-cost system enables women of all ages to be screened for breast cancer in GP surgeries, or alternative high street locations, with results that are now comparable with traditional X-ray mammograms.

T
TechniScan Medical Systems

TechniScan has developed a whole breast ultrasound imaging system

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.